Postoperative Radiation Dose for Inguinofemoral Lymph Nodes with Extracapsular Extension
For inguinofemoral lymph nodes with extracapsular extension (ENE) after surgical resection, deliver 60 Gy in 30 fractions over 6 weeks using 2 Gy per fraction with a shrinking field technique. 1
Dose Specification Based on ENE Status
The NCCN guidelines for squamous cell skin cancer provide the most direct and applicable dosing recommendations for postoperative radiation to inguinofemoral nodes with ENE:
- With ENE (groin/axilla): 60 Gy over 6 weeks (2 Gy per fraction)
- Without ENE (groin/axilla): 54 Gy over 5.4 weeks (2 Gy per fraction) 1
This represents a 6 Gy dose escalation when ENE is present, reflecting the significantly worse prognosis and higher risk of local recurrence associated with extracapsular spread.
Supporting Evidence from Vulvar Cancer Guidelines
The vulvar cancer literature reinforces this approach. Patients with ENE-positive nodes derive significant survival benefit from adjuvant chemoradiation, with studies showing improved outcomes when adequate radiation doses are delivered to areas of extranodal extension 2. The GOG 37 trial demonstrated that radiation therapy significantly improved 2-year survival (68% vs 54%, p=0.03) in node-positive vulvar cancers, with the greatest benefit seen in patients with multiple positive nodes or gross nodal disease—clinical scenarios often associated with ENE 2.
Critical Technical Considerations
Field Coverage and Planning
- Use CT-based treatment planning to ensure adequate depth coverage 3, 4
- Critical pitfall: Historical studies using a 3 cm depth prescription point showed inadequate nodal coverage, as 24 of 81 superficial inguinal nodes and ALL deep inguinal nodes were beyond 3 cm depth 4
- Include both superficial and deep inguinofemoral node basins in the treatment volume
- Consider concurrent platinum-based chemotherapy (typically cisplatin) for radiosensitization 2, 5
Dose Constraints
- The 60 Gy dose to ENE-positive nodes may be limited by normal tissue constraints, particularly femoral head tolerance 3
- Use shrinking field technique to spare normal tissues while maintaining adequate dose to areas of gross disease 1
- Attempt to reduce dose to femoral heads throughout treatment 3
Context from Head and Neck Cancer
Recent evidence from head and neck squamous cell carcinoma (where ENE is extensively studied) suggests that the extent of ENE matters significantly. A 4 mm cutoff for ENE extent better predicts benefit from adjuvant chemoradiation than the traditional 2 mm cutoff 6. While this specific cutoff hasn't been validated for inguinofemoral nodes, it underscores that more extensive ENE warrants more aggressive treatment, supporting the 60 Gy dose recommendation.
Concurrent Chemotherapy
Strongly consider concurrent cisplatin-based chemotherapy with the radiation, particularly for ENE-positive disease 2, 5. The combination provides additional tumor cytotoxicity and has been shown to improve outcomes in node-positive disease, though it increases acute toxicity. Alternative regimens include 5-FU plus mitomycin C for patients with compromised renal function 7.
Common Pitfalls to Avoid
- Underdosing due to inadequate depth assessment: Always use CT-based planning rather than arbitrary depth prescriptions
- Inadequate field coverage: Ensure both superficial and deep inguinal nodes are encompassed
- Omitting concurrent chemotherapy: The radiosensitization benefit is substantial in high-risk disease
- Treating ENE-positive nodes the same as ENE-negative nodes: The 6 Gy dose escalation (54→60 Gy) is evidence-based and clinically significant